Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsTumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
/in Glioblastoma, International Publications, IOZK VeröffentlichungenOncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
/in Breast Cancer, International Publications, Newcastle Disease VirusHN Protein of Newcastle Disease Virus Induces Apoptosis Through SAPK/JNK Pathway
/in International Publications, Newcastle Disease VirusRecombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus, Pancreatic CancerProspective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
/in Breast Cancer, Dendritic Cells, International PublicationsTherapeutic hyperthermia: The old, the new, and the upcoming
/in Hyperthermia, International PublicationsDendritic cell-based immunotherapy targeting Wilms‘ tumor 1 in patients with recurrent malignant glioma
/in Dendritic Cells, Glioblastoma, International PublicationsEnhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study
/in Colorectal Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer